Effects of Hydrotherapy During Post-COVID-19 Rehabilitation (HydroCoVital A)

August 21, 2025 updated by: Prof. Dr. Andreas Rembert Koczulla, Schön Klinik Berchtesgadener Land

Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial

This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.

Study Overview

Detailed Description

Patients recovering from Post-COVID Syndrome often experience persistent fatigue, autonomic dysregulation, microcirculatory disturbances, and low-grade inflammation, all of which may hinder their return to full function. Kneipp hydrotherapy-using cold water applications-can address these pathophysiological changes through several mechanisms:

Autonomic regulation: Cold stimuli trigger parasympathetic activation and improve sympathovagal balance, helping to stabilize heart rate variability and reduce symptoms of dysautonomia often seen in Post-COVID.

Enhanced microcirculation: Repeated vasoconstriction and reactive vasodilation promote endothelial function and tissue perfusion, which may alleviate muscle aches, dizziness, and fatigue by improving oxygen and nutrient delivery.

Anti-inflammatory effects: Hydrothermal stimuli have been shown to modulate cytokine profiles, increasing anti-inflammatory mediators and potentially dampening the persistent, low-grade inflammation implicated in Post-COVID pathophysiology.

Musculoskeletal recovery: Thermo-mechanical stimulation relaxes tense muscle fibers, reduces pain perception, and supports gradual increases in physical capacity, all of which are important for overcoming Post-COVID deconditioning.

Taken together, these effects suggest that adjunctive cold water hydrotherapy could accelerate functional recovery, reduce symptom burden, and enhance quality of life in Post-COVID rehabilitation.

Baseline Assessments:

At baseline, demographic data including sex, age, height, and weight will be collected. Participants will report their current main Post-COVID symptoms, which will be categorized into symptom clusters: Fatigue (A), Cognitive (B), and Somatic (C). Smoking history will be assessed, including smoking status (current, former, or never), number of cigarettes per day, years of smoking, and pack-years.

The time (in months) since the COVID-19 infection that led to Post-COVID syndrome will be documented, along with the number of COVID-19 vaccinations received at the time of infection. Employment status will be recorded, distinguishing between full-time or part-time employment, COVID-related work disability, retirement, unemployment, or disability pension.

Comorbidities will be documented across the following categories: cardiovascular, pulmonary, cerebrovascular, metabolic, musculoskeletal, psychiatric, and other conditions. The severity of the acute COVID-19 illness will be assessed using the WHO Clinical Progression Scale, including information on any hospital admission and length of stay (in days).

Pulmonary function testing at baseline (V1) will include FEV₁, FVC, FEV₁/FVC ratio, and total lung capacity (TLC), all expressed as percent predicted. Autonomic function will be evaluated using the Schellong test. Vascular status will be assessed by four-limb blood pressure measurement. Additionally, self-reported work ability and the number of Post-COVID-related sick leave days within the past 12 weeks will be recorded.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Bavaria
      • Schönau am Königssee, Bavaria, Germany, 83471
        • Recruiting
        • Schön Klinik Berchtesgadener Land
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)
  • Barthel-Index >80
  • Referred to the reference center for Post-COVID rehabilitation
  • Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability
  • Written informed consent

Exclusion Criteria:

  • Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)
  • Prior regular practice of Kneipp applications

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Post-COVID Rehabilitation with hydrotherapy
Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
Active Comparator: Post-COVID Rehabilitation without hydrotherapy
3-week inpatient multimodal inpatient rehabilitation program without hydrotherapy
same rehabilitation program than the experimental group but without hydrotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health-related quality of life by Short Form-12 Health Survey (SF-12)
Time Frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Change in the Short Form-12 physical and mental component summary scores
From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fatigue severity by Fatigue Severity Scale
Time Frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Change in Fatigue Severity Scale score
From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Sleep quality by Pittsburgh Sleep Quality Index
Time Frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Change in Pittsburgh Sleep Quality Index score
From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Health status by EuroQol-5 Dimensions-5 Levels
Time Frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Change in EuroQol-5 Dimensions-5 Levels questionnaire score
From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Autonomic function (heart rate variability by photoplethysmography)
Time Frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Change in heart rate variability (root mean square of successive differences) measured by Kyto 2935 via photoplethysmography
Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Resting blood pressure (systolic and diastolic)
Time Frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Change in morning resting systolic and diastolic blood pressure
Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Post-COVID work-absence days
Time Frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Number of days of work absence due to Post-COVID-19 symptoms during the past 12-weeks
From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Long-term quality of life by Short Form-12
Time Frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Change in Short Form-12 scores at follow-up
From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Long-term fatigue by Fatigue Severity Scale
Time Frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Change in Fatigue Severity Scale score at follow-up
From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Adherence to hydrotherapy
Time Frame: During the 3-week intervention phase (up to Visit 2) and over the 6-month follow-up period (to Visit 4)

Proportion of prescribed hydrotherapy applications in the intervention group performed, as recorded in diary or app.

Short-term Adherence: During the 3-week intervention phase, patients are considered "adherent" if they perform at least one hydrotherapy session per day on at least 75% of study days. We will compare health improvements between high-adherence and low-adherence participants.

Long-term Adherence and Effects: Over the 3- and 6-month follow-up, "adherent" patients are those who continue self-administered hydrotherapy at least four times per week on at least 75% of follow-up weeks. We will assess whether these patients sustain greater gains in quality of life.

During the 3-week intervention phase (up to Visit 2) and over the 6-month follow-up period (to Visit 4)
Adverse events recording
Time Frame: From start of intervention (Visit 1) through end of study (Visit 4, 6-month follow-up)
Number and severity of adverse events related to Kneipp hydrotherapy
From start of intervention (Visit 1) through end of study (Visit 4, 6-month follow-up)
Long-term heart rate variability changes (HRV)
Time Frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Change in heart rate variability parameters (root mean square of successive differences) measured by photoplethysmography. At follow-up visits patients will measure HRV for 7 consecutive days
From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Post-exertional malaise severity
Time Frame: From baseline (Visit 1) to 6-month (Visit 4) follow-up
Change in Post-Exertional Malaise score measured by the DePaul Symptom Questionnaire-Post-Exertional Malaise
From baseline (Visit 1) to 6-month (Visit 4) follow-up
Daily well-being documentation
Time Frame: Daily throughout the intervention and 6 months follow-up phase (Visit 1 to Visit 4)
Self-reported daily well-being recorded via digital diary on a scale from 0 to 100
Daily throughout the intervention and 6 months follow-up phase (Visit 1 to Visit 4)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rembert Koczulla, MD, Schön Klinik Berchtesgadener Land

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 21, 2025

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

June 5, 2025

First Submitted That Met QC Criteria

June 5, 2025

First Posted (Actual)

June 10, 2025

Study Record Updates

Last Update Posted (Estimated)

August 28, 2025

Last Update Submitted That Met QC Criteria

August 21, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post COVID Syndrome

Clinical Trials on Standard rehabilitation plus cold water hydrotherapy

Subscribe